Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Inks Supply and Distribution Agreement for Microbiome MDx

NEW YORK (GenomeWeb) – Bio-Rad has signed a supply and distribution agreement with Oslo-based firm Genetic Analysis for an assay to detect imbalances in the gut microbiome.

Genetic Analysis manufactures a CE-marked gut microbiota test called GA-Map for detecting bacterial imbalances to diagnose and manage conditions such as inflammatory bowel disease and irritable bowel syndrome.

"With the GA-map technology, we will be able to offer products that can analyze the microbiome associated with gut dysbiosis, which affects the quality of life of many patients around the world and can result in serious health problems," said John Hertia, executive vice president of Bio-Rad and president of the firm's clinical diagnostics group. 

The firms said in a statement that recent success with the dysbiosis test has also triggered a further investment and development agreement for additional microbiome tests.

Ronny Hermansen, CEO of Genetic Analysis, noted that during the past year the body of evidence supporting the use of GA-map has grown considerably. "Bio-Rad has the market knowledge and necessary resources to accelerate the uptake of this technology by clinicians worldwide," Hermansen said, adding that Generic Analysis anticipates further developing its product portfolio with Bio-Rad's continued support.

GA-map uses 16S rRNA amplification and a number of proprietary technologies, according to Genetic Analysis' website. These include its ProbeTool software program to find combinations of DNA probes that can be used in the test, a unique universal primer pair, a novel probe labeling method to obtain relative quantities of bacteria, and a database combining microbiota array data and patient health profiles.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.